Connection
David Camidge to Oncolytic Virotherapy
This is a "connection" page, showing publications David Camidge has written about Oncolytic Virotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.057 |
|
|
|
-
Naing A, Khalil D, Rosen O, Camidge DR, Lillie T, Ji RR, Stacey A, Thomas M, Rosen L. First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. J Immunother Cancer. 2024 Oct 15; 12(10).
Score: 0.057